NextCure, Inc. reported the full year ended December 31, 2025 results: net income Net loss was $55.8 million.
“NextCure, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December31, 2025.”
NextCure, Inc. — fact timeline
Source-grounded facts extracted from NextCure, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
NextCure, Inc. issued up to an aggregate of 1,815,049 shares of Common Stock of warrant to certain institutional and accredited investors for $8.519 per Pre-Funded Warrant.
“(ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 1,815,049 shares of Common Stock (the “Pre-Funded Warrant Shares”) at a purchase price of $8.519 per Pre-Funded Warrant”
NextCure, Inc. issued 708,428 shares of common stock to certain institutional and accredited investors for $8.52 per share.
“On November 12, 2025, NextCure, Inc. (“NextCure” or the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional and accredited investors (each, a “Purchaser” and collectively, the “Purchasers”) for a private placement (the “Offering”) of an aggregate of (i) 708,428 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a purchase price of $8.52 per share”
NextCure, Inc.: Amendment to Certificate of Incorporation to effect a 1:12 reverse stock split (effective 2025-07-14).
“On July 14, 2025, NextCure, Inc., a Delaware corporation (the “ Company ”), effected a one-for-twelve (1:12) reverse stock split (“ Reverse Stock Split ”) of the Company’s common stock, par value $0.001 (the “ Common Stock ”).”
NextCure, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“January 31, 2025, NextCure, Inc. (the “Company”, “we”, “us”, or “our”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying us that the closing price of our common stock over the prior 30 consecutive business days had fallen below $1.00 per share, which is the minimum average closing price required to maintain listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have 180 calendar days, or until J”
NextCure, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“January 31, 2025, NextCure, Inc. (the “Company”, “we”, “us”, or “our”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying us that the cl”
Han Myint retired as Chief Medical Officer at NextCure, Inc..
“Dr. Han Myint, M.D. notified NextCure, Inc. (the “Company”) of his plan to retire from his position as Chief Medical Officer of the Company, effective July 1, 2024.”
NextCure, Inc. reported first quarter 2024 results: net income Net loss was $17.1 million.
“NextCure, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.”
NextCure, Inc. reported financial results for the year ended December 31, 2023.
“On March 21, 2024, NextCure, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2023.”
NextCure, Inc. reported quarter ended September 30, 2023 results: net income Net loss was $14.3 million for the quarter ended September 30, 2023.
“NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results”
NextCure, Inc. reported quarter ended June 30, 2023 results: net income Net loss was $17.9 million.
“On August 3, 2023, NextCure, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023.”
Garry A. Nicholson resigned as Director at NextCure, Inc..
“On July 15, 2023, Garry A. Nicholson resigned from the board of directors of NextCure, Inc. (the “Company”), effective August 15, 2023.”
NextCure, Inc.: Amended and restated bylaws to update adjournment procedures, stockholder meeting lists, director nomination rules, and universal proxy rules compliance (effective 2023-06-22).
“On June 22, 2023, the board of directors (the “Board”) of NextCure, Inc. (the “Company”) approved and adopted the Second Amended and Restated Bylaws of the Company (the “A&R Bylaws”).”
NextCure, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2023 at the 2023-06-22 meeting.
“On June 22, 2023, the Company held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders: (i) elected the three Class I members of the Board, each to serve for a three-year term expiring at the Company’s 2026 Annual Meeting of Stockholders and until such director’s earlier death, resignation, or removal from the Board; and (ii) ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”
NextCure, Inc. shareholders approved Election of Class I Directors at the 2023-06-22 meeting.
“On June 22, 2023, the Company held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders: (i) elected the three Class I members of the Board, each to serve for a three-year term expiring at the Company’s 2026 Annual Meeting of Stockholders and until such director’s earlier death, resignation, or removal from the Board; and (ii) ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”
NextCure, Inc. reported financial results for the quarter ended March 31, 2023.
“NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases today provided a business update and reported first quarter 2023 financial results.”
NextCure, Inc. reported the quarter ended September 30, 2022 results: net income Net loss was $18.9 million for the quarter ended September 30, 2022.
“Net loss was $18.9 million for the quarter ended September 30, 202 2, as compared with a net loss of $17.9 million for the quarter ended September 30, 2021.”
Ellen Feigal, M.D. was elected as Director at NextCure, Inc..
“elected Anne Borgman, M.D., and Ellen Feigal, M.D., to the Board.”
Anne Borgman, M.D. was elected as Director at NextCure, Inc..
“elected Anne Borgman, M.D., and Ellen Feigal, M.D., to the Board.”
Dr. Stella Xu resigned as Director at NextCure, Inc..
“On September 21, 2021, Dr. Stella Xu notified NextCure, Inc. (the “Company”) of her resignation from the Board of Directors, effective September 30, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.